Oncotarget publishes the findings of numerous scientific studies on oncology and other medical-related areas weekly. It is a peer-reviewed publication. Its parent journal is Impact Journals. The Oncotarget published its premiere article approximately seven years ago. This journal has since gone ahead to publish literally thousands of other peer-reviewed and reportedly insightful articles. The articles published therein are all in English, which means that a very large part of the world’s population can read them. Officially, Oncotarget is slotted in under open-access journals. In other words, any individual interested in scientific research has a good chance of using the journal.
The Oncotarget Team
The Oncotarget team is said by online sources to be dedicated, qualified and talented. Their research record is noted to be impressive as well. Headed by chief editors professor Mikhail Blagoskloklonny and professor Andre V. Gudkov, the group makes certain that all the articles published in their publication are informational and meet high quality standards.
The chief editors are well-known, reputable professors at the Roswell Park Cancer Institute located in Buffalo, New York. Gudkov has made a major contribution to the study of numerous cancer therapies, especially concerning molecular targets and drug discovery. Blagosklonny alone has written over 250 articles in various peer-reviewed journals.
Oncotarget’s Impact Factor
During the journal’s first year in print, Oncotarget garnered an IF (impact factor) of 4.78 and was read by people in 493 cities. (That’s noteworthy for a new publication.) The following year, it was received in 1450 cities, and its IF was up to 6.636.
In 2013 Oncotarget officially registered the “highest impact factor” of 6.727. More than 2,200 cities were receiving the journal that year. The next year Oncotatget had an IF that dropped to 6.359 but this was still actually a high and consistent figure. More importantly, it was also reaching approximately 4,000 cities. More recently the journal had a steady IF of 5.168 and was being received in over 30,000 cities. The bottom line is that Oncotarget’s reception has actually multiplied by close to 100 times over the seven years it has been in existence.
To know more click here